Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Central Nervous System

The Question That Remains Unanswered: What Migh...

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease...

Jun 17, 2020

Alzheimer’s Disease Market | Biogen | Aducanumab | Eisai| Biogen | Aducanumab | Eisai |
Can Aducanumab Solve the Puzzle Of Alzheimer’s?

Alzheimer's Disease Market finally witnessed the approval of standard therapy, Aducanumab, by Biogen. What impact does it hold for the future? Demographic or population ageing is a global and dominant phenomenon of the 21st century. Different geographies are experiencing population ageing at different rates. As ...

Find More
Technology-and-Alzheimer’s
When Technological Innovations Help in Remembering for People Living with Alzheimer’s

Alzheimer's is a progressive neurological disorder associated with the degeneration of brain cells with time. As the disease progresses it causes severe impact on the memory, thinking, and overall behavior of the individual, at the later phases it becomes even challenging to perform simple day to day tasks.  ...

Find More
pharma-news
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;

Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...

Find More

More Views & Analysis

What are the 10 early signs of Alzheimer’s that are overlooked?

Alzheimer’s is a brain disease, associated with the degeneration of brain cells. It is an irreversible and progressive disease that generally affects people aged above 65 years but in very rare cases, early-onset has also been noticed in the late ’40s. The AD affects memory, reasoning and cognitive skills of the pe...

Find More

Alzheimer’s-Disease-Market-Scenario
An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario?

The ageing population is a global phenomenon. According to the UN’s “World Population Prospects 2019” by 2100, the world’s population is projected to reach approximately 10.9 billion. Moreover, between 2020 and 2100, the number of people ages 80 and older is expected to increase from 146 million to 881 million. ...

Find More

pharma-news
Startup focuses tumors with CAR-T; AbCellera grabs USD 105M; Gilead inks USD 2B deal; GSK’s anti-BCMA antibody receives a boost

The startup focuses on glioblastoma tumors with CAR-T therapy. CAR-T technology that involves genetically modifying a patient’s immune cells to recognize and attack cancer. However, while the innovation has helped patients with certain blood malignancies, progress in solid tumors remains restricted. The scien...

Find More

pharma-news
CanSino deals with Precision; Atea raises USD 215 M; Applied Molecular Transport targets for USD 100 M IPO; Cell therapy repairs multiple sclerosis in mice

CanSino adds mRNA with Precision NanoSystems  CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...

Find More

pharma-news
Acquisition of Stemline; Roche’s Elecsys Anti-SARS-CoV-2 antibody test; Newron’s abandonment of STARS trial

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...

Find More

pharma-news
Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...

Find More

BK Virus Infection , a member of the polyomavirus family, is typically associated with patients who .....

Find More

A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....

Find More

Pyelonephritis (Kidney infection) is an infection of the kidney, which is a consequence of urinary t.....

Find More

Cell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....

Find More

Real-world evidence (RWE) is used in an exponential way to guide payment decisions and access system.....

Find More

Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the a.....

Find More